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a  b  s  t  r  a  c  t
The  charge  variations  of  therapeutic  monoclonal  antibody  reveal  important  information  of  the  post-
translational  modiﬁcations  that may  potentially  impact  the  potency  and  safety  of  pharmaceutical
products,  especially  during  the  evaluation  of  biosimilarity  of  therapeutic  proteins.  In this  work,  a  novel
SpeB-based  proteolysis  strategy  coupling  with  imaged  capillary  isoelectric  focusing  was  developed  for
the determination  of  domain-speciﬁc  charge  heterogeneities  of innovator  and  generic Rituximab  drug
products  from  United  States,  European  and  Indian  markets.  It was  observed  that  innovator  Rituximab
from  the  United  States  and  Europe  share  highly  similar  peak  distributions  and  charge  heterogeneities
with  26.2–26.6%  Fc/2,  28.9–29.3%  LC  and  44.4–44.5%  Fd  peak  areas  detected,  respectively,  while  multiple
basic  variations  of  Fc/2  and  less  acidic  LC  and  Fd  species  were  found  from  generic  Rituximab  from  India
with  20.9%  Fc/2,  32.3%  LC  and  46.9%  Fd  peak  areas  detected.  It  was  also  demonstrated  that  structural
changes  caused  by  Carboxypeptidase  B treatment  and  deamidation  study  at pH extremes  could  be  sensi-IEF
eamidation
onoclonal antibody
Ab
tively  captured  with  the  established  method,  with  the  results  further  indicating  that  the  generic  product’s
basic  variations  of  Fc/2  were  un-cleaved  Lysine  residues,  while  the  lack of  certain  acidic  peaks  on  LC and
Fd probably  was  due  to  the lower  level  of  deamidation.  This  new  strategy  could  become  a useful  tool  to
reveal  domain-speciﬁc  charge  heterogeneities  proﬁles  of a variety  of therapeutic  monoclonal  antibodies
in regulated  environments.
©  2016  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Introduction
Biosimilars are biotherapeutic products with highly sim-
lar safety, efﬁcacy and quality compared to licensed “ref-
rence” biotherapeutic products [1]. The bioequivalence and
ost-effectiveness have attracted more intensive research and
ommercialization of biosimilars, especially in the emerging phar-
aceutical markets [2]. With the patent expiration by 2020 of 12
iotherapeutic products with more than $67 billion global sales
3], a major opportunity has been foreseen for the development of
iosimilar products. Biopharmaceutical recombinant monoclonal
ntibodies (mAb) are a class of biotech-derived molecules with
ighly complex secondary and tertiary structures as well as multi-
le post-translational modiﬁcations (PTM) [4]. They are considered
mongst the most important treatments in oncology and inﬂam-
∗ Corresponding authors.
E-mail addresses: zichuan.zhang@ppdi.com (Z. Zhang), julia.ding@ppdi.com
J. Ding).
ttp://dx.doi.org/10.1016/j.jchromb.2016.03.031
570-0232/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
matory diseases with dramatic growth in sales during the past
years [5]. Compared to other biologics, the development and char-
acterization of biosimilar mAbs are considered much more difﬁcult.
Unlike small molecules, biosimilar mAbs cannot be proven to be
identical due to the hundreds of variables during production using
different cell lines by different manufacturers. The minor changes
from chemical and enzymatic modiﬁcations during manufacturing
process could potentially result in meaningfully clinical differ-
ences in efﬁcacy and safety [6]. To date, only biosimilar Inﬂiximab
has been approved by European Medicines Agency (EMA). In the
United States, no biosimilar mAb  has been approved by the United
States Food and Drug Administration (FDA) so far [7,8]. While
the development of biosimilars is encouraged with the published
guidelines from regulatory authorities [9–11], there is a critical
need to develop fast and sensitive analytical strategies to detect
the variations among biosimilar and reference mAbs.Comparative analytical studies are critical that inform the next
steps of demonstration of similarity based on the assessments
as speciﬁed in the recently published guideline from FDA [12].
While mass spectrometry based methods such as peptide mapping
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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s a powerful tool to identify biosimilar PTMs, its application as
 validated method in regulated environment is limited through
he whole stages of biosimilar chemistry, manufacturing and con-
rols (CMC), and often suffers from the degradations, additives and
uffering salts in biopharmaceutical products. Sensitive and robust
eparation and detection methods for the qualitatively and quanti-
atively detection of minor structural changes from different angles
re considered the bottleneck to demonstrate similarity. The charge
eterogeneity of proteins reveals important structural information
or the determination of similarity. Due to the existence of multiple
TMs and potential degradations, mAbs exhibit charge hetero-
eneities known as acidic and basic species when detected by
on exchange chromatography (IEC) and isoelectric focusing (IEF).
n addition, capillary zone electrophoresis (CZE) is also employed
or charge-based separation. Imaged Capillary isoelectric focusing
iCIEF) is a technique that separates and focuses proteins and pep-
ides based on their isoelectric points (pI). Through co-migration
ith carrier ampholytes in coated silica capillary, proteins and pep-
ides carrying different charges could be concentrated to a position
ithin the capillary depending on their isoelectric points (pI)  in
inutes [13] with the whole-column imaging that avoids the step
f sample migration after focusing and prevents band broaden-
ng [14,15]. Differnent from CZE [16] of which separation is based
n both charge and molecular size, iCIEF has gained wide applica-
ions in biopharmaceutical testings due to its enhanced sensitivity
nd robustness from the combination of separation and focusing.
ompared to IEC, iCIEF features faster separation, higher resolu-
ion and a much simpliﬁed method development procedure that
an be easily transferred to analysis of a variety of similar protein
roducts [17]. These advantages have made it an ideal technique to
istinguish the minor structural differences that exhibiting charge
ariations between reference and biosimilar mAbs in regulated
nvironment.
It has been recently reported that substantial affects to the
otency and pharmacokinetics, depending on the nature, degree
nd location of modiﬁcations, may  be caused by using chemically-
odiﬁed antibodies, especially if the modiﬁcation occurs in the
omplementarity determining regions (CDRs) [18]. Thus, it is
mportant to characterize the domain-speciﬁc modiﬁcations of
iosimilar mAbs, as reﬂected in their charge proﬁles, to demon-
trate equivalent potency and safety as reference products. A
ecent effort towards domain-speciﬁc characterization of thera-
eutic mAbs is the development of middle-up and middle-down
roteolysis with IdeS (Immunoglobulin-degrading enzyme of
treptococcus). Compared to conventional analysis of charge varia-
ions [19–22], in middle-up or middle-down proteolysis mAbs were
ragmented to LC (light chain), Fc/2 (fragment crystallizable region)
nd Fd (the heavy chain portion of the fragment-antigen binding
egion), which facilitates the PTM identiﬁcations to each domain
23–32]. Recombinantly modiﬁed SpeB (FabULOUS®) from S. pyo-
enes is a newly commercialized cysteine protease that cleaves
he upper hinge region of IgG in reduced condition. Compared to
deS, SpeB proteolysis occurs to the upper hinge region in reduc-
ng condition. It could be adopted as a complementary proteolysisl antibodies with iCIEF analysis.
pathway than IdeS with simpler procedure, applied to certain IgGs
(such as mouse IgG1) that are resistant to IdeS, or combined with
IdeS for the isolation of hinge region. To date, there is no report
discussing SpeB’s capability and speciﬁcity for the proteolysis of
therapeutic mAbs. Further, there is no study on the comparison
of domain-speciﬁc charge heterogeneities among reference and
biosimilar mAbs using either IdeS or SpeB proteolysis.
In this work, we  report the ﬁrst SpeB proteolysis to therapeu-
tic mAb  products. In addition to its coupling to iCIEF separation,
the capability of combining with multiple treatments including
Carboxypeptidase B treatment and forced degradation was demon-
strated to help determine the differences found from each domain
(Fig. 1). This strategy was  applied to the domain-speciﬁc character-
ization of the charge heterogeneities among innovator Rituximab
manufactured in different sites from the United States and Europe,
and non-FDA approved generic Rituximab from India.
2. Experimenal
2.1. Chemicals and materials
Innovator Rituximab samples (10 mg/mL  in formulation) were
purchased from United Sates (Rituxan, Genentech, South San
Francisco, California) and European (Mabthera, Roche, Basel,
Switzerland) marketplaces and stored in 5 ◦C. Generic Rituximab
sample (10 mg/mL  in formulation) was  purchased Indian (Reditux,
Dr. Reddy’s Laboratories, Hyderabad, India) marketplace and stored
in 5 ◦C. Carboxypeptidase B from human pancreas (CPB), iodoac-
etamide (IAM), tris (2-carboxyl) phosphine (TCEP), Pharmalyte 5–8
and Pharmalyte 8–10.5 were purchased from Sigma Aldrich (St.
Louis, Missouri). Dithiothreitol (DTT) was purchased from Pierce
(Rockford, Illinois), with 1 N HCl and 1 N NaOH from J. T. Baker
(Center Valley, Pennsylvania). 0.5% Methyl Cellulose, 1% Methyl
Cellulose, Anolyte solution (0.08 M Phosphoric acid in 0.1% Methyl
Cellulose), Catholyte solution (0.1 M NaOH in 0.1% Methyl Cellu-
lose), pI marker 5.85 and pI marker 10.45 were purchased from
Protein Simple (Santa Clara, California). SpeB enzyme (FabULOUS®)
was purchased from Genovis (Lund, Sweden). GIBCO 1 × PBS, pH
7.2 was  from Life Technology (Grand Island, New York). All water
used was  doubly distilled on a Millipore ﬁltration system (Bedford,
Massachusetts).
2.2. SpeB proteolysis
Lyophilized SpeB was dissolved to 5 unit/L with puriﬁed water
and mixed well. To each 10 L of 10 mg/mL  Rituximab samples,
added 45 L of puriﬁed water, 45 L of 1 × PBS at pH 7.2, 20 L of 5
unit/L SpeB and 5 L of 125 mM DTT in 1 × PBS at pH 7.2. For CPB
treated samples and degradated samples, the volume of puriﬁed
water and PBS were adjusted to keep comparable combined salt
concentration and same ﬁnal volume. The samples were mixed and
incubated at 37 ◦C for 1 h. After incubation, combined 120 L of
digested samples with 16 L of 300 mM IAM and 24 L of 1 × PBS
at pH 7.2. Mixed well and placed in dark for 30 min. The samples
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ere kept in 5 ◦C and prepared for iCIEF analysis within the same
ay.
.3. Intact and reduced sample preparations
In addition to SpeB-digested samples, intact and reduced
amples were prepared for comparison. For intact samples, the
ituximab sample was diluted to 0.6 mg/mL  by combining 6 L
f 10 mg/mL  Rituximab sample, 39 L puriﬁed water and 55 L
 × PBS at pH 7.2. For reduced samples, combined 10 L of
0 mg/mL  Rituximab samples with 65 L of puriﬁed water, 45 L
f 1 × PBS at pH 7.2 and 5 L of 125 mM DTT in 1 × PBS at pH 7.2.
ixed well and placed in the dark for 30 min. After reducing, 120 L
f reduced samples was combined with 16 L of 300 mM IAM and
4 L of 1 × PBS at pH 7.2. Mixed well and placed in the dark for
0 min. The samples were kept in 5 ◦C and prepared for iCIEF anal-
sis within the same day.
.4. Capillary gel electrophoresis
Capillary gel electrophoresis (CGE) was used to conﬁrm correct
rotein cleavage after SpeB proteolysis. 15 L of 250 mM IAM was
ixed with 225 L of SDS-MW sample buffer (Beckman Coulter,
ndianapolis, Indiana). 20 L of SpeB digested Rituximab sample
as mixed with 80 L IAM/SDS-MW sample buffer, and denatured
or 10 min  at 70 ◦C. The sample was brieﬂy centrifuged and the top
ortion was transferred to the sample vials for analysis. CGE was
erformed using a bare-fused silica capillary (50 m i.d. × 30 cm)
n a PA-800 Plus system (Beckman Coulter, Indianapolis, Indiana)
nder reverse polarity at −15 kV for 35 min. A detection window
as opened on the capillary at 20 cm from the inlet end for UV
etection at 220 nm.
.5. Desalting
To test if sample desalting is needed, 40 L of SpeB digested
ample was mixed with 360 L of puriﬁed water. Vortexed and
ransferred the solution to a centrifuge ﬁlter with 10 k nominal
olecular weight level (Millipore, Bedford, Massachusetts). Cen-
rifuged at 10,000 rpm for 15 min, then reverted the ﬁlter in a new
ube and centrifuged at 1000 rpm for 2 min  to collect the desalted
amples. Added puriﬁed water to the desalted sample to make up
o the original volume.
.6. Carboxypeptidase B (CPB) treatment
For CPB treatment, combined 10 L of 10 mg/mL  Rituximab
amples with 37.5 L of puriﬁed water and 2.5 L of 1 mg/mL  CPB.
ently mixed and centrifuged at 3000 rpm for 5 min. Incubated at
5 ◦C for 2 h in a water bath. The 2 mg/mL  CPB treated Rituximab
amples were used as the stock samples for the following-up SpeB
roteolysis and iCIEF analysis.
.7. Deamidation at pH extremes
For each of the reference and biosimilar Rituximab samples at
0 mg/mL, prepared stock samples by diluting to 2 mg/mL  with
uriﬁed water. For base treatment, adjusted the pH of each stock
ample to 10 with 0.1 N NaOH. For acid treatment, adjusted the pH
f each stock sample to 4 with 0.25 N HCl. Gently vortexed to mix
nd seal each sample vial with Paraﬁlm (Chicago, Illinois). Placed
he samples in a water bath at 40 ◦C. For base treatment, collected
he degradated samples at 0 h, 4 h, 8 h, 12 h and 24 h. Prepared three
echnical replicates for each time point. For acid treatment, col-
ected the degradated samples at 24 h. For each of the collected
amples, adjusted the pH back to approximately 6.5 with 0.1 N HClB 1020 (2016) 148–157
or 0.25 N NaOH, respectively, and diluted to 1.0 mg/mL  with 1 × PBS
at pH 7.2. Stored in −80 ◦C before analysis.
2.8. iCIEF analysis
The proﬁling of charge heterogeneity was performed on an
iCE3 system coupled with an Alcott 719 autosampler and a ﬂuo-
rocarbon coated capillary (100 m i.d. × 50 mm)  (Protein Simple,
Santa Clara, California). The instrument parameters were set as fol-
lows: pre-focusing time 1 min  at 1500 V, focusing time 10 min  at
3000 V, sample injection time 76 s, buffer injection and wash time
114 s, sample temperature 5 ◦C. The CIEF ampholyte solution con-
sisted of 2% of Pharmalyte 5–8, 2% of Pharmalyte 8–10.5, 0.5% of
pI marker 5.85, 0.5% of pI marker 10.45, 0.35% of methylcellulose
and 7 M urea in water. Before analysis, Rituximab samples (intact,
reduced and digested) at 0.6 mg/mL  were mixed with ampholyte
solution at a ratio of 1:3 and centrifuged at 10,000 rpm for 3 min.
All samples were analyzed within 12 h after preparation. The elec-
tropherograms were calibrated with the pI markers and converted
to Empower software (Waters, Milford, Massachusetts) for data
analysis.
3. Results and discussion
3.1. SpeB proteolysis and iCIEF method development
Compared to IdeS that requires follow-up reducing and desalt-
ing steps, SpeB cuts the upper hinge region of IgG1 between T225
and C226 in reduced condition, thus generating LC, Fd and Fc/2
simultaneously with a simpliﬁed sample preparation procedure.
During the course of this study, it was  discovered that in order to
maintain the enzyme speciﬁcity, the buffering condition needs to
be strictly controlled. As an example shown in Fig. S1 in the sup-
porting material, using 5 mM tris (2-carboxyl) phosphine (TCEP)
as reducing reagent in 1 × PBS buffer at pH 7.2 resulted in non-
speciﬁc cleavage of a target IgG due to the change of buffering pH
caused by TCEP, while using 5 mM Dithiothreitol (DTT) instead of
TCEP generated correct LC, Fd and Fc/2 fragments (Fig. S2). Also, it
was noticed that if the buffering pH falls out of the manufacturer’s
suggested range (6.5–8.0) during any stage of the analysis, SpeB
will lose its speciﬁcity to IgG upper hinge region but not its activ-
ity. Thus, enzyme deactivation is necessary if SpeB proteolysis is
coupled with follow-up processing that may  change the buffering
condition.
As the pH of CIEF ampholyte solution was higher than 8, when
digested samples were mixed with ampholyte for iCIEF analysis,
unspeciﬁc cleavage occurred to the LC, Fd and Fc/2 and generated
smaller fragments, especially when the protein was unfolded in
denaturing condition (Fig. 2A and 2B). In order to deactivate SpeB
before iCIEF analysis to avoid unspeciﬁc cleavage, 30 mM IAM was
added immediately after digestion to block the cysteine residues
to de-active SpeB enzyme. As shown in Fig. 2C and 2D, three major
peaks were observed from both non-denaturing (pI  7.1, 9.4, 10.0)
and denaturing (pI  7.1, 8.8, 9.8) conditions. It was  conﬁrmed that
the pI 9.4 peak in non-denaturing condition was  a small fragment
that could be ﬁltered through 10 kD centrifuge ﬁlter (Fig. 2E), indi-
cating it was not the LC peak (23 kD). Due to the existence of strong
interface, LC is still linked to Fd/HC through non-covalent bond after
partial reducing in non-denaturing condition [33]. The result was
conﬁrmed in reduce-only Rituximab that LC and HC (heavy chain)
could not be distinguished in non-denaturing condition (Fig. S3A).
When urea was added to the ampholyte, both LC and HC peaks
present in reduced condition (Fig. S3B) and all of the three major
peaks including LC, Fd and Fc/2 were observed after SpeB proteol-
ysis (Fig. 2D).
Z. Zhang et al. / J. Chromatogr. B 1020 (2016) 148–157 151
Fig. 2. SpeB proteolysis and iCIEF method development for Rituximab. (A and B): without deactivating SpeB in non-denaturing condition (A) and denaturing condition (B).
(C  and D): SpeB deactivated, without desalting in non-denaturing condition (C) and denaturingcondition (D). (E and F): SpeB deactivated, with desalting in non-denaturing
condition (E) and denaturing condition (F).
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Table 1
Summary of domain-speciﬁc differences among innovator and generic Rituximab from iCIEF electropherograms.
Fragments Rituxan Mabthera Reditux
%Area Peaks Detected %Area Peaks Detected %Area Peaks Detected
Fc/2 26.2 Two major peaks between pI 7.0–7.2.
One acid front and one basic shoulder
26.6 Same with Rituxan 20.9 Two peaks between pI 7.0–7.2 but with
much lower intensities. Multiple basic
variations between pI 7.3–7.8 (with
un-cleaved C-terminal Lysine residues)
count about 45% of total Fc/2 peak area
LC  29.3 Single light chain at pI 8.8–8.9 with a
low acidic front
28.9 Same with Rituxan 32.3 Single light chain at pI 8.8–8.9. Acidic
front not detected
Fd  44.4 One major Fd peak at pI 9.8 with two 44.5 Same with Rituxan 46.9 One major Fd peak at pI 9.8 with one
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aacidic species (pI 9.5, 9.7) and one basic
species at pI 9.9
Generally, the salt concentration in the CIEF sample should be
ower than 15 mM to avoid overheating and instable pH gradi-
nt [34]. Here we compared results with desalted and un-desalted
amples. It was found that the low salt concentration resulted in
onger separation time, so the LC peak could not be fully focused
ithin 10 min  (Fig. 2F). Increasing focusing time to 15 min  gen-
rated fully focused LC, similar to 10 min  focusing of un-desalted
ample, but distorted peaks and more spikes were observed due to
onger focusing. Our test results indicated that consistent data could
e generated with a relatively higher salt concentration (approxi-
ately 30–35 mM)  without sample desalting, as shown in Fig. 2D.
.2. Comparison of the reference and biosimilar rituximab
To evaluate the equivalence of biosimilar drug products, the
odiﬁcations to the protein need to be investigated and clariﬁed.
his is extremely difﬁcult for biosimilar mAbs due to the existence
f various PTMs from the different cell lines and processing used
uring manufacturing. The only previous comparative analytical
tudy on Rituximab was reported by Wang et al. on comparing Rit-
xan from the United States and Reditux from India by employing
iquid chromatography-mass spectrometry [35]. It was concluded
hat the differences include N-terminal pyroglutamation and C-
erminal lysine cleavage. In this work, we report a much simpler
nd faster workﬂow employing SpeB proteolysis and iCIEF. As iCIEF
ombines the high resolution of capillary electrophoresis and the
apability of focused charged variations of proteins, it is a widely-
dopted technique to proﬁle protein charge heterogeneities and
etect the small changes exhibiting charge variation that may
ardly be observed by other techniques. These features make it an
deal method for comparative study and quality control of biosim-
lars in regulated laboratories. Here, the iCIEF electropherograms
ere compared among intact, reduced and SpeB-digested Ritux-
mab samples obtained from innovator in different sites (Rituxan
rom Genentech, United States and Mabthera from Roche, Europe)
nd the generic form (Reditux from Dr. Reddy’s Laboratory, India).
As summarized in Fig. 3, distinct peak patterns with high resolu-
ion were obtained for the intact, reduced and digested Rituximab
amples using the established method. As intact proteins in dena-
uring condition, the innovator Rituximab samples share almost
dentical peak proﬁles (Fig. 3A and 3B), while distinguishable differ-
nt charged variations were observed from the generic Rituximab
Fig. 3C). The electropherograms of reduced samples identiﬁed LC
nd HC peaks, as the LC peak shared same pI value in both reduced
Fig. 3D-3F) and SpeB-digested (Fig. 3G-3I) samples. It further indi-
ated that the charge heterogeneities mainly come from the IgG
C peak which could be attributed to the existence of a variety
f possible modiﬁcations on the heavy chain. Compared to inno-
ator Rituximab, more basic variations with a lower abundance of
cidic front were observed from the HC of generic Rituximab. Theacidic species at pI 9.7 and one basic
species at pI 9.9. No pI 9.5 peak
region-speciﬁc differences were characterized with SpeB-digested
samples. As shown in Fig. 3G-3I, the HC peak was replaced by the
Fc/2 peak centered at pI 7.2 and the Fd peak centered at pI 9.8.
These measured pI values are consistent with the calculated values
(7.2–7.7 and 9.2–9.3, respectively, by Peptide Properties Calculator
from Innovagen), considering the IAM alkylation slightly shifted the
pI of Fd. Innovator Rituximab products manufactured from US and
Europe again share identical proﬁles after proteolysis. Two major
peaks were observed from Fc/2 region due to the two major pri-
mary glycoforms as previously reported [34]. The same peaks also
were observed from the generic Rituximab sample, but with much
lower intensity, while two major basic species ranging from pI 7.3
to 7.6 presented in the electropherogram of digested Reditux. Pre-
vious study on glycan proﬁling indicates that generic Rituximab
contains same glycoforms as innovator Rituximab [35], thus the
basic species are most possibly un-cleaved Lysine residues from
protein C-terminus. The LC proﬁles of all three Rituximab samples
are comparable, except that an acidic front with low intensity at pI
8.7–8.8 is undetectable from Reditux sample. For Fd region, both
innovator Rituximab samples exhibit same peak proﬁles including
one major Fd peak at pI 9.8 with two  acidic species (pI  9.5, 9.7) and
one basic shoulder at pI 9.9. Generic Rituximab has similar peak
pattern except missing the acidic peak at pI 9.5. A summary of the
domain-speciﬁc differences is concluded in Table 1.
3.3. Characterization of the C-terminal Lysine variation
Incompletely cleaved heavy chain C-terminal Lysine often is
observed from monoclonal antibodies after mammalian cell cul-
ture. As a result, multiple charge variations will present in CIEF
electropherogram due to the mAb  isoforms with 0–2 Lysine
residues at C-terminus. CPB is a basic Carboxypeptidase that pref-
erentially cleaves the C-terminal Lysine [36]. In order to investigate
if the basic species on the Fc/2 region of generic Rituximab were a
result from the un-cleaved Lysine residues on the C-terminus, Rit-
uximab samples were mixed with CPB and incubated for 2 h prior to
the SpeB proteolysis and iCIEF analysis. No detectable change was
observed from both innovator Rituximab samples in their intact,
reduced and digested forms after CPB treatment (Fig.S4). The peak
type and intensity of Fc/2 domain remained the same, indicating
complete removal of C-terminal Lysine from innovator Rituximab
samples. For the generic Rituximab (Reditux), CPB treatment did
not change the peak proﬁles of LC and Fd region, however, the basic
species of Fc/2 disappeared with enhanced Fc/2 major peaks (Fig. 4),
which shows similar peak patterns as innovator Rituximab. These
results demonstrated that the difference on Fc/2 region between
innovator and generic Rituximab is the complete or partial removal
of C-terminal Lysine.
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F rs. A-C
( ). G-I:
3
mig. 3. Electropherograms of intact, reduced and SpeB-digested Rituximab biosimila
C).  D-F: The electropherogram of reduced Rituxan (D), Mabthera (E) and Reditux (F.4. Deamidation study of rituximab
Asparagine deamidation is a major degradation pathway of
Abs that could be impacted by conditions such as buffer type,: The electropherogram of intact (untreated) Rituxan (A), Mabthera (B) and Reditux
 The electropherogram of SpeB digested Rituxan (G), Mabthera (H) and Reditux (I).pH and temperature [37,38]. The chemical deamidation path-
way involves the formation of succinimide intermediate followed
by hydrolysis to aspartic acid and iso-aspartic acid. A recently
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ublished research revealed the deamidation site of Rituximab
Mabthera) at N55, N319, N329 and N388 in stressed conditions
sing LC coupling to a hybrid Orbitrap mass spectrometer [39].
ere, we compared the deamidation proﬁles of reference and
iosimilar Rituximab under pH extremes, followed by SpeB pro-
eolysis and iCIEF analysis.
The base treatment was performed by adjusting the buffering
H to 10 with 0.1 N NaOH with incubation at 40 ◦C. The degra-
ated samples were collected at 0 h, 4 h, 8 h, 12 h and 24 h and
eutralized immediately (n = 3 for each time point). Fig. 5 labels all
f the identiﬁed peaks from the innovator and generic Rituximab
amples after 24 h incubation. The innovator Rituximab products
Rituxan, Mabthera) share almost identical deamidated peaks from
ach domain, including Fc/2 A1 (deamidated Fc/2 Peak 2), Fc/2 A2
deamidated Fc/2 Peak 1), LC A2 (deamidated LC), Fd A2 and Fd A3
both deamidated Fd), as well as Fc/2 B1, LC B1 and Fd B2, which
re possibly succinimide intermediates that shift the pIs to more
asic. Compared to innovator products, generic Rituximab exhibits
ery similar deamidation proﬁle on LC and Fd domains. The miss-
ng Fd A2 peak from untreated Reditux electropherogram (Fig. 3I)
lso was observed after degradation with a similar percent area
o that in innovator products, indicating a lower level of deamida-
ion in untreated generic Rituximab. In the Fc/2 domain of Reditux,
ajor deamidated peaks were observed on Fc/2 A1 and Fc/2 B3 due
o the existence of C-terminal Lysine. The kinetic study within 24 h
ndicated that the deamidation rates of each domain were different
ith the highest percent area of deamidated peaks reached from 8 h represent (A) intact condition, (B) after reducing and (C) after SpeB proteolysis.
to 24 h. However, similar degradation kinetics was observed among
the reference and biosimilar Rituximab samples. A summary of the
percent peak area of each peak observed from each time point after
base treatment is shown in Table 2.
Compared to pH 10, it has been found that Rituximab in its
formulation has a much lower degradation rate and is more vul-
nerable to precipitation at an acidic environment. Here we only
investigated the degradation proﬁles of reference and biosimi-
lar Rituximab samples after 24 h incubation at pH 4 to obtain
detectable degradation peaks and avoid precipitation. As shown in
Fig. 6, no detectable acidic variants were observed after degrada-
tion. However, slightly increased basic shoulders or basic tails were
found from all three domains, which most probably indicating the
formation of succinimide intermediate. Comparable to base treat-
ment, similar degradation products were observed from innovator
and generic Rituximab, except for the Fc/2 domain of Reditux due
to the existence of C-terminal Lysine residues.
4. Conclusions
In this work, a new strategy to characterize the charge het-
erogeneities of biosimilar mAbs has been developed by coupling
SpeB proteolysis with iCIEF analysis. This strategy is applied to the
characterization of the reference and biosimilar Rituximab from
United States, European and Indian markets. The LC, Fd and Fc/2
fragments as well as their PTMs could be well resolved in the
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Table  2
Comparison of reference and biosimilar Rituximab samples after base treatment (pH 10, 0–24 h at 40 ◦C).
Peak Name Percent Peak Area (Average of n = 3)
Rituxan Mebthera Reditux
0 h 4 h 8 h 12 h 24 h 0 h 4 h 8 h 12 h 24 h 0 h 4 h 8 h 12 h 24 h
Fc/2 A2 0.0 0.0 0.0 1.6 1.3 0.0 0.0 0.0 1.0 1.1 ND ND ND ND ND
Fc/2  A1 2.2 4.4 6.1 5.7 6.1 2.7 5.5 6.0 4.9 5.8 0.0 0.0 1.7 1.4 2.2
Fc/2  Peak 1 8.8 8.0 7.7 7.5 7.3 8.8 8.3 7.7 7.7 7.5 5.6 6.3 5.4 4.8 4.7
Fc/2  Peak 2 15.2 13.5 9.7 6.2 7.1 15.1 12.2 10.3 8.6 8.0 5.8 5.7 5.3 5.2 4.4
Fc/2  B1 0.0 0.0 0.0 0.9 1.3 0.0 0.0 0.0 1.5 1.5 ND ND ND ND ND
Fc/2  B2 ND* ND ND ND ND ND ND ND ND ND 2.6 2.3 1.8 3.6 4.0
Fc/2  B3 ND ND ND ND ND ND ND ND ND ND 0.6 0.8 0.5 2.2 2.3
Fc/2  B4 ND ND ND ND ND ND ND ND ND ND 4.3 3.4 3.0 3.8 2.9
Fc/2  B5 ND ND ND ND ND ND ND ND ND ND 2.0 2.2 1.9 1.2 1.3
LC-A2  0.0 1.3 2.9 2.2 2.4 0.0 1.5 2.1 1.7 1.5 1.0 1.6 1.3 1.9 2.3
LC-A1  0.0 0.0 2.3 1.9 1.4 0.0 0.0 1.2 1.2 1.1 ND ND ND ND ND
LC  29.3 28.8 27.6 27.9 28.1 28.9 28.5 26.9 28.5 28.4 31.3 31.0 30.2 30.7 29.9
LC-B1  0.0 0.0 0.8 0.8 0.7 0.0 0.0 0.5 0.6 0.5 ND ND ND ND ND
Fd-A3  0.0 0.5 1.3 1.4 1.4 0.0 0.9 1.4 1.0 0.9 0.0 0.0 1.0 0.0 1.0
Fd-A2  2.4 3.2 5.3 6.1 5.6 2.5 4.4 5.6 4.6 5.0 0.0 3.0 5.0 2.5 5.3
Fd-A1  6.9 8.1 8.5 9.2 8.4 6.8 8.4 8.6 8.0 8.2 7.7 9.0 9.3 8.5 9.2
Fd  33.4 29.8 24.3 25.2 27.2 33.4 28.1 26.2 29.0 28.6 37.2 32.0 29.8 32.5 28.2
1.9 
0.8 
*
e
c
F
UFd-B1  1.7 1.7 1.6 1.7 1.2 1.8 
Fd-B2  0.0 0.5 1.7 1.7 0.6 0.0 ND: Not detectable.
lectropherogram, enabling quantitative study of domain-speciﬁc
harge heterogeneities. Our results conclude that the innovator Rit-
ig. 5. Electropherograms of degradated Rituximab biosimilars after base treatment at p
.S.,  (B) Mabthera from Europe and (C) Reditux from India.1.8 1.3 1.5 2.0 1.9 1.9 1.7 1.7
1.7 0.3 0.4 0.0 0.9 1.8 0.0 0.6uximab products from the United States and Europe share similar
peak proﬁles and percentages of each domain, while the generic
H 10 for 24-hr incubation at 40 ◦C. Electropherograms represent (A) Rituxan from
156 Z. Zhang et al. / J. Chromatogr. B 1020 (2016) 148–157
F  at pH
(
R
t
a
o
e
n
o
s
p
t
h
a
i
A
S
s
c
A
i
0
[
[
[
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ituximab from India features partially cleaved Lysine residue on
he protein C-terminus as well as a lower level of deamidation. As
 demonstration, these results could be applied to the assessment
f similarity during biosimilar product development, and provide
ssential information for the determination of approaches for the
ext step animal and clinical studies. Compared to most previ-
us comparative studies relying on mass spectrometry, this new
trategy sensitively reveals domain-speciﬁc charge heterogeneities
roﬁles of therapeutic monoclonal antibodies using routine elec-
rophoretic method used in biopharmaceutical industry, which
ighlights its great potential to be applied to the characterization
nd comparison of a variety of therapeutic monoclonal antibodies
n biosimilar chemistry, manufacturing and controls.
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